Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $12
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $35 to $12.
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $35 to $12.